Product Description: VR23 is a small molecule that potently inhibits the activities of trypsin-like proteasomes (IC50=1 nM), chymotrypsin-like proteasomes (IC50=50-100 nM), and caspase-like proteasomes (IC50=3 μM).
Applications: Cancer-Kinase/protease
Formula: C19H16ClN5O6S
References: [1]Pundir S, et al. VR23: A Quinoline-Sulfonyl Hybrid Proteasome Inhibitor That Selectively Kills Cancer via Cyclin E-Mediated Centrosome Amplification. Cancer Res. 2015 Oct 1;75(19):4164-4175./[2]Lee Hoyun, et al. Preparation of quinoline sulfonyl derivatives for the treatment of cancer. From PCT Int. Appl. (2014), WO 2014134705 A1 20140912.
CAS Number: 1624602-30-7
Molecular Weight: 477.88
Compound Purity: 99.58
Research Area: Metabolic Disease; Cancer
Solubility: DMSO : 33.33 mg/mL (ultrasonic)
Target: Apoptosis;Proteasome